Humacyte (HUMA) Interest & Investment Income (2020 - 2026)
Humacyte (HUMA) posted quarterly Interest & Investment Income of $330000.0 for Q1 2026, down 50.15% year-over-year from $662000.0 in Q1 2025, and down 34.39% quarter-over-quarter from $503000.0 in Q4 2025.
Humacyte (HUMA) Interest & Investment Income (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Interest & Investment Income for 7 consecutive years, with $330000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 50.15% year-over-year to $330000.0; the TTM figure through Mar 2026 stood at $2.3 million (down 39.63% YoY), while the FY2025 annual figure was $2.6 million, down 36.96% from the prior year.
- Interest & Investment Income retreated to $330000.0 in Q1 2026 per HUMA's latest filing, from $503000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.5 million in Q2 2023 and bottomed at $31000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $889235.3 across 5 years, with a median of $883000.0 in 2022.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 29333.33% — and 2026, when it slumped 50.15%.
- Humacyte's Interest & Investment Income stood at $1.4 million in 2022, then slipped by 19.09% to $1.1 million in 2023, then decreased by 25.52% to $852000.0 in 2024, then tumbled by 40.96% to $503000.0 in 2025, then plunged by 34.39% to $330000.0 in 2026.
- Business Quant data shows HUMA's Interest & Investment Income at $330000.0 in Q1 2026, $503000.0 in Q4 2025, and $590000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Humacyte | 150.77 Mn | 150.77 Mn | -825,000.00 | 388,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 388,000.00 |
| Mar 31, 2026 | 330,000.00 |
| Dec 31, 2025 | 503,000.00 |
| Sep 30, 2025 | 590,000.00 |
| Jun 30, 2025 | 832,000.00 |
| Mar 31, 2025 | 662,000.00 |
| Dec 31, 2024 | 852,000.00 |
| Sep 30, 2024 | 911,000.00 |
| Jun 30, 2024 | 1.31 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | 1.37 Mn |
| Jun 30, 2023 | 1.48 Mn |
| Mar 31, 2023 | 1.48 Mn |
| Dec 31, 2022 | 1.41 Mn |
| Sep 30, 2022 | 883,000.00 |
| Jun 30, 2022 | 301,000.00 |
| Mar 31, 2022 | 31,000.00 |
| Dec 31, 2021 | 10,000.00 |
| Sep 30, 2021 | 3,000.00 |